Most animal cells express mixtures of the three subtypes of inositol 1,4,5-trisphosphate receptor (IP 3 R) encoded by vertebrate genomes. Activation of each subtype by different agonists has not hitherto been examined in cells expressing defined homogenous populations of IP 3 R. Here we measure Ca 2+ release evoked by synthetic analogues of IP 3 using a Ca The potency of an analogue, (1,4,6)IP 3 , in which the orientations of the 2-and 3-hydroxyl groups were inverted, was also reduced similarly for all three IP 3 R subtypes. Most analogues of IP 3 interact similarly with the three IP 3 R subtypes, but the decrease in potency accompanying removal of the 1-phosphate from (1,4,5)IP 3 was least for IP 3 R3. Addition of a large chromophore (malachite green) to the 1-phosphate of (1,4,5)IP 3 only modestly reduced potency suggesting that similar analogues could be used to measure (1,4,5)IP 3 binding optically. These data provide the first structure-activity analyses of key IP 3 analogues using homogenous populations of each mammalian IP 3 R subtype. They demonstrate broadly similar structure-activity relationships for all mammalian IP 3 R subtypes and establish the potential utility of (1,4,5)IP 3 analogues with chromophores attached to the 1-position.
Introduction
Most animal cells express inositol 1,4,5-trisphosphate receptors (IP 3 R), which fulfil an essential role in linking the many cell-surface receptors that stimulate IP 3 formation to release of Ca 2+ from the endoplasmic reticulum [1] . Vertebrates have genes for three IP 3 R subunits, while invertebrates have only a single IP 3 R gene. All functional IP 3 R are tetrameric assemblies of these subunits. The similar primary sequences of the IP 3 R subunits suggest that all IP 3 R are likely to share similar structures, although we presently have only a limited understanding of the structure of the entire IP 3 R [1, 2] . Each subunit has an N-terminal region to which IP 3 binds. This region comprises the N-terminal suppressor domain (SD, residues 1-223) and the IP 3 -binding core (IBC, residues 224-604 in IP 3 R1, Figure 1A ), which is alone sufficient to bind IP 3 with appropriate selectivity [3] . The SD both modulates the affinity of the IBC for agonists and provides an essential link between IP 3 binding and opening of the pore [4, 5, 6, 7] . A large cytoplasmic region separates the N-terminal from the six transmembrane domains. The last pair of these, together with the intervening luminal loop, form the Ca 2+ -permeable pore [8] ( Figure 1A ). Each subunit terminates in a short C-terminal tail, which has also been implicated in the regulation of gating [9] . The diversity provided by three genes is further increased by multiple splice variants of at least two of the three IP 3 R subtypes (IP 3 R1 and IP 3 R2), by formation of homo-or hetero-tetrameric assemblies of IP 3 R subunits, by association with an enormous diversity of modulatory proteins and by post-translational modifications [10] . At present, we have only a limited understanding of the functional significance of this complexity for IP 3 -evoked Ca 2+ signals in native tissues. The broadly similar structures of the three IP 3 R subunits are matched by many shared functional properties, most notably coregulation of all IP 3 R by IP 3 and Ca 2+ [10, 11] . Nevertheless, there are differences in the patterns of expression of IP 3 R in different tissues [12, 13] , in their subcellular distributions [14, 15] , sensitivities to IP 3 [16] , modulation by accessory proteins and additional signals [17, 18, 19] , and in the functional consequences of IP 3 R ablation [20, 21] . Heterogeneous populations of IP 3 R in most cells make it difficult to establish clearly the characteristics of each IP 3 R subtype and to define their functional roles. A better knowledge of the ligand recognition properties of the three IP 3 R3 subtypes is needed if ligands selective for IP 3 R subtypes are to be developed to help resolve these problems. All known high-affinity agonists of IP 3 R retain structures equivalent to the 4,5-bisphosphate and 6-hydroxyl groups of (1,4,5)IP 3 ( Figure 1B ) [22] . The only exception is a low-affinity analogue of adenophostin A (30-dephosphoadenophostin A) in which interactions between the adenine moiety and IP 3 R appear partially to compensate for loss of a phosphate (equivalent to the 5-phosphate of (1,4,5)IP 3 ) within the critical bisphosphate moiety [23] . Here we use a selection of synthetic analogues of IP 3 that preserve the key structures of the highaffinity agonists to assess their activity at each IP 3 R subtype.
Materials and Methods

Materials
Thapsigargin was from Alomone Laboratories (Jerusalem, Israel). The structures of the ligands used and their abbreviations are shown in Figure 1B. (1,4,5)IP 3 was from Alexis Biochemicals (Nottingham, U.K.). 3-deoxy(1,4,5)IP 3 , (1,3,4)IP 3 and (1,3,4,5)IP 4 were from Calbiochem (Nottingham, U.K.). (1,4,6)IP 3 from both Alexis Biochemicals and synthesized as reported previously [24] was used. Malachite green IP 3 (MG(1,4,5)IP 3 ) was synthesized using the methods described by Inoue et al. [25] . (4,5)IP 2 [26] , 2-deoxy(1,4,5)IP 3 [27] and synthetic (1,3,4,5)IP 4 [28] were synthesized as previously described. All synthesized ligands were purified by ion-exchange chromatography, fully characterized by the usual spectroscopic methods and accurately quantified by total phosphate assay. 3 H-IP 3 (185 Bq/mmol) was from PerkinElmer (Bucks, U.K.).
Anti-peptide antisera to peptides conserved in all mammalian IP 3 R subtypes (AbC, residues 62-75 of rat IP 3 R1) or unique to IP 3 R1 (Ab1, residues 2724-2739) or IP 3 R2 (Ab2, residues 2685-2701) were described previously [29] . A monoclonal antibody that recognizes N-terminal residues (22-230) of IP 3 R3 (Ab3) was from BD Transduction Laboratories (Oxford, U.K.). Anti-b-actin antibody was from AbCam (Cambridge, U.K.). Donkey secondary antibodies (anti-rabbit or anti-mouse) conjugated to horseradish peroxidase were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Sources of other materials are provided in earlier publications [30, 31] .
Cell Culture
DT40 cells lacking genes for all three IP 3 R subtypes (DT40-KO cells) [32] and the same cells stably expressing rat IP 3 R1 (GenBank accession number GQ233032.1) [33] , mouse IP 3 R2 (GU980658.1) [31] or rat IP 3 R3 (GQ233031.1) [34] were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 1% heat-inactivated chicken serum, 2 mM glutamine and 50 mM 2-mercaptoethanol at 37uC in 95% air and 5% CO 2 . Cells were passaged every 2 days when they reached a density of ,1.5610 6 cells/mL.
Immunoblotting
Cells (,7610 7 ) were centrifuged (650 g, 5 min), resuspended in Hepes-buffered saline (HBS), re-centrifuged, and the pellet was solubilized in 1 mL of medium containing 140 mM NaCl, 5 mM NaF, 10 mM Tris, 1 mM Na 4 P 2 O 7 , 0.4 mM Na 3 VO 4 , 1% Triton X-100 and a protease inhibitor tablet (1 tablet/10 mL, Roche 6 cells stably expressing IP 3 R1, IP 3 R2 or IP 3 R3, or from DT40-KO cells (KO). The antisera used are selective for IP 3 R1-3 (Ab1-3) or they interact equally with all three IP 3 R subtypes (AbC) [29] (see Materials). An antiserum to b-actin was used to confirm the equivalent loading of lanes. Quantitative analysis of AbC immunoreactivity from 3 similar gels was used to establish expression levels of the three IP 3 R subtypes relative to IP 3 R3 (means 6 SEM, n = 3) (lower panel Diagnostics, Mannheim, Germany). HBS had the following composition: 135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl 2 , 1.5 mM CaCl 2 , 11.6 mM Hepes, 11.5 mM glucose, pH 7.3. The solubilized cells were sonicated on ice (Trans Scientific 1420 sonicator, 50-60 Hz, 3610 s), incubated with gentle rotation for 1 h at 2uC and then centrifuged (6000 g, 10 min). A sample of the supernatant (13 mL) was mixed with DL-dithiothreitol (2 mL, 100 mM) and NuPAGE LDS sample buffer (5 mL, Invitrogen, Paisley, U.K.). After heating (70uC, 10 min), 20-mL samples were loaded onto NuPAGE 3-8% Tris acetate gels for SDS-PAGE using Novex Tris acetate buffer (Invitrogen). Broad range spectrum marker and MagicMark molecular weight markers (Invitrogen) were used to monitor protein migration during SDS-PAGE and for calibration, respectively. After transfer to a PVDF membrane using an iBlot dry-blotting system (Invitrogen), the membrane was blocked by incubation (1 h) with Tris-buffered saline (TBS) containing 5% non-fat dry milk. It was then incubated with primary antiserum (1:1000 and 1:10,000 for IP 3 R and b-actin antibodies, respectively) in TBS containing 2.5% w/v BSA for 12 h. TBS had the following composition: 140 mM NaCl, 20 mM Tris, 0.1% v/v Tween, pH 7.6. After incubation with primary antibodies, the blots were washed in TBS (365 min), incubated with horseradish peroxidase-conjugated secondary antibodies (1:1000, donkey anti-rabbit or donkey anti-mouse) for 1 h in TBS supplemented with 2.5% BSA, and washed again (365 min). Bands were detected using Supersignal West Pico chemiluminescent substrate (ThermoScientific, Rockford, IL, U.S.A.) and quantified using GeneTools software (Syngene, Frederick, MD, U.S.A.). ] of ,220 nM (after addition of 1.5 mM MgATP) and with carbonyl cyanide 4-trifluoromethoxy-phenyl hydrazone (FCCP, 10 mM) to inhibit mitochondrial Ca 2+ uptake. Cells were distributed (5610 5 cells/well) into half area 96-well, black-walled, poly-lysine-coated plates and centrifuged (300 g, 2 min). Fluorescence (excitation and emission wavelengths of 485 nm and 520 nm, respectively) was recorded at 1-s intervals using a FlexStation TM 3 fluorescence plate reader (Molecular Devices, Berkshire, U.K.) at 20uC. Addition of MgATP (1.5 mM) allowed Ca 2+ uptake into the intracellular stores, and after 150 s, IP 3 (or its analogues) was added together with thapsigargin (1 mM) to prevent further Ca 2+ uptake. IP 3 -evoked Ca 2+ release is expressed as a fraction of that released by addition of ionomycin (1 mM) [35] . ] of 220 nM were incubated with 3 H-IP 3 (1.5 nM) and appropriate concentrations of competing ligand at 4uC [4] . After 5 min, during which equilibrium was attained, the reactions were terminated by centrifugation (2000 g).
Measurement of IP
The supernatant was removed and the pellet was washed (500 mL CLM) and then solubilized (200 mL CLM with 1% v/v Triton-X-100) before determining its radioactivity using Ecoscint A scintillation cocktail (National Diagnostics, Atlanta, GA, USA, 1 mL). Total 
Homology Modelling and Ligand Docking
Sequence alignments were performed using MUSCLE (http:// www.ebi.ac.uk/Tools/msa/muscle/). Structural homology models were built in Modeller 9.10 [36] using templates of crystal structures of the IBC (Protein Data Bank: 1N4K) and SD (Protein Data Bank: 1XZZ). The geometric qualities of the models were evaluated with the Molprobity server [37] . Finally, the N-terminal regions of mouse IP 3 R2 and rat IP 3 R3 comprising the modelled SD and IBC structures of each were reconstructed by aligning the individual domains against cognate regions of the NT of rat IP 3 R1 (Protein Data Bank: 3UJ4) [7] using UCSF Chimera 1.6.1 [38] .
We used docking of IP 3 analogues into a rigid IBC and subsequent superposition of the structure onto a model of the entire IP 3 R solely to assess whether full-length IP 3 R was likely to bind the analogues without steric clashes. Docking of IP 3 analogues was performed using the IBC (Protein Data Bank: 1N4K) [3] and AutoDock Vina 1.1.2 [39] . Prior to docking, bound (1,4,5)IP 3 and all water molecules (except those within 5 Å of the IP 3 -binding site) were removed. The search space comprised a grid of 20620620 points, each separated by 0.375 Å , around the IP 3 -binding site. Ligands (except (1,4,5)IP 3 ) were drawn and energy-minimized with MM2 force field using ChemBioOffice 2008 (http://www.cambridgesoft.com). Polar hydrogens and the Gasteiger partial atomic charges were then added to the protein and ligands using AutoDockTools (http://autodock.scripps.edu/ resources/adt), and the prepared structures were used as input files for docking. Only the best pose is considered for each ligand. For MG(1,4,5)IP 3 , the ligand was superposed onto (1,4,5)IP 3 within the NT monomer (Protein Data Bank: 3UJ0A) and the complex (with (1,4,5)IP 3 -removed) was energy-minimized using MMFF94 Forcefield [40] . PyMol was used to present docked structures (http://pymol.sourceforge.net/).
Results
Expression of Mammalian IP 3 Receptor Subtypes in DT40 Cells
Immunoblotting with IP 3 R subtype-selective antisera (Ab1-3) established that each of the stable DT40 cell lines specifically expressed only a single IP 3 R subtype (Figure 2A ). An antiserum that recognizes a peptide sequence present in all mammalian IP 3 R subtypes (AbC) [29] was used to quantify relative levels of IP 3 R expression in the three cell lines (Figure 2A ). The results demonstrate that, relative to IP 3 R3 (100%), levels of expression of IP 3 R1 and IP 3 R2 were 7168% and 4865%, respectively (Figure 2A ). Because the density of IP 3 R may affect the sensitivity of intracellular Ca 2+ stores to IP 3 [6] and it is impracticable to generate cell lines expressing identical levels of each IP 3 R subtype, comparisons of the relative potencies of IP 3 analogues for each IP 3 R subtype are expressed relative to the potency of (1, A low-affinity luminal Ca 2+ indicator was used to report the free Ca 2+ concentration within the endoplasmic reticulum of permeabilized DT40 cells ( Figure 2B ). IP 3 failed to evoke Ca 2+ release in DT40-KO cells, which lack IP 3 R (not shown) [34] , but it was effective in DT40 cells stably expressing each of the three IP 3 R subtypes ( Figure 2B and C) Figure 2C ). Notwithstanding the moderate differences in IP 3 R expression in the different DT40 cell lines (Figure 2A) , the relative sensitivities of IP 3 R1-3 to IP 3 in these assays (IP 3 R1,I-P 3 R2.IP 3 R3) are consistent with a general consensus that IP 3 R3 is the least sensitive of the IP 3 R subtypes [16] .
Interactions of IP 3 Metabolites with IP 3 Receptor Subtypes Table 1 ). The purity of (1,3,4,5)IP 4 supplied by Calbiochem is only ,98%. We were therefore concerned that its effects on Ca Figures 3B and C) . The much reduced potency of (1,3,4,5)IP 4 is consistent with loss of the 3-hydroxyl group reducing potency (Table 1 and see below) and with docking analyses, which suggest that although the 3-phosphate can be accommodated, the orientations of the phosphate groups are slightly distorted relative to (1,4,5)IP 3 bound to the IBC ( Figure 3F ).
It has been suggested that ( Figure 3D) . The results, which show that (1,3,4,5)IP 4 has no effect on the response to any concentration of (1,4,5)IP 3 ( Figure 3E ), provide no support for the suggestion that (1,3,4,5)IP 4 potentiates IP 3 -evoked Ca 2+ release [42] . Furthermore, the lack of inhibition of IP 3 -evoked Ca 2+ release by (1,3,4,5)IP 4 demonstrates that it is not a partial agonist of IP 3 R. We conclude that (1,3,4,5)IP 4 is a low-affinity full agonist of all three IP 3 R subtypes.
Dephosphorylation of (1,3,4,5)IP 4 by IP 3 5-phosphatase produces (1,3,4)IP 3 ( Figure 3A) , which can accumulate to concentrations considerably exceeding that of (1,4,5)IP 3 during sustained stimulation [44] . (1,3,4) Tables 1 and 2 ). Contamination of (4,5)IP 2 with (1,4,5)IP 3 cannot explain this activity because (4,5)IP 2 was prepared by total synthesis and purified by ion-exchange chromatography [26] . This is consistent with previous functional analyses of native IP 3 R [45] and with the ability of (4,5)IP 2 to compete with 3 H-(1,4,5)IP 3 for binding to these IP 3 R subtypes heterologously expressed in Sf9 cells [46] . However, the difference in potency of (1,4,5)IP 3 and (4,5)IP 2 at IP 3 R3 was only ,24-fold (DpEC 50 = 1.3860.06) ( Figure 4B , Table 2 ). Our results suggest that although removal of the 1-phosphate from (1,4,5)IP 3 reduces potency at all IP 3 R subtypes, IP 3 R3 is least affected. Within the IBC of IP 3 R1, the 1-phosphate of (1,4,5)IP 3 interacts directly with R568 and, via water, with K569 [3] (Figure 4C ). These residues and their immediate neighbours are conserved in IP 3 R2 and IP 3 R3 ( Figure 4C ). The only residues known to interact directly with (1,4,5)IP 3 are within the IBC ( Figure 1A ) and primary sequences of the IBC are highly conserved between IP 3 R subtypes. It is therefore unsurprising that homology models based on the IBC of IP 3 R1 [3] suggest almost indistinguishable structures for the IBCs from IP 3 R2 and IP 3 R3 ( Figure 4D) . Furthermore, the IBCs from the three IP 3 R subtypes have the same affinity for (1,4,5)IP 3 [16] . However, both fulllength IP 3 R and the NT from different IP 3 R subtypes differ in their affinities for (1,4,5)IP 3 . These observations demonstrate that interactions between the IBC and other parts of the IP 3 R, notably the suppressor domain (SD, residues 1-223), influence ligand binding [4, 16] . The complexity of these interactions between the IBC and other domains together with the need for only very modest conformational differences between subtypes to account for the small differences in ligand potency make it difficult to define the residues responsible for modulating the interactions between the IBC and the 1-phosphate group of (1,4,5)IP 3 in IP 3 R3. The structure of (1,4,5)IP 3 bound to the IBC of IP 3 R1 shows the 2-hydroxyl group of (1,4,5)IP 3 exposed to solvent ( Figure 1A ) [3] and previous structure-activity studies of native IP 3 R suggested that removal of the 2-hydroxyl moiety from (1,4,5)IP 3 to give 2-deoxy(1,4,5)IP 3 minimally affects activity [4, 46] . Our results confirm that observation for all three IP 3 R subtypes: 2-deoxy(1,4,5)IP 3 and (1,4,5)IP 3 are equipotent at all three IP 3 R subtypes ( Figures 5A and B, Tables 1 and 2) .
Removal of the 3-hydroxyl of (1,4,5)IP 3 (3-deoxy(1,4,5)IP 3 ) caused a ,40-fold decrease in potency (DpEC 50 ,1.6) that was similar for all three IP 3 R subtypes ( Figures 5C and D , Tables 1  and 2 ). This decrease is larger than that observed for either Ca 2+ release from cells expressing largely IP 3 R1 (,3-fold) [47] or for binding to heterologously expressed IP 3 R1-3 (7-20-fold) [46] .
(1,4,6)IP 3 is an analogue of (1,4,5)IP 3 in which the orientations of the 2-and 3-hydroxyl groups are inverted ( Figures 1B and 6A) . Figure 1B ) was originally synthesized to explore its potential as a ligand of IP 3 R that might allow chromophore-assisted laser inactivation (CALI) of IP 3 R [25, 48] . The first study, using surface plasmon resonance to assess binding to an N-terminal fragment of IP 3 R1 (residues 1-885), surprisingly suggested that MG(1,4,5)IP 3 had ,170-fold greater affinity than (1,4,5)IP 3 , whereas fluorescein similarly attached to the 1-position of (1,4,5)IP 3 had no significant effect on affinity [25] . The results were important because they suggested that MG(1,4,5)IP 3 might be the ligand with the highest known affinity for IP 3 R, and they were unexpected because disrupting interaction of the 1-phosphate group of (1,4,5)IP 3 with the IP 3 R would be expected to reduce affinity ( Figure 4 and Table 1 ) [45] . A subsequent study of Ca 2+ release from permeabilized smooth muscle cells concluded that the EC 50 for MG(1,4,5)IP 3 was ,7-fold higher than that for (1,4,5)IP 3 [25] . The disparity between the reported very high affinity of MG(1,4,5)IP 3 for the N-terminal of IP 3 R1 and its modest potency in functional assays of smooth muscle has not been explained. We considered two possibilities. MG(1,4,5)IP 3 may be a high-affinity partial agonist or it may differ massively in its affinity for IP 3 R1 and the endogenous IP 3 R of smooth muscle.
Our results indicate that MG(1,4,5)IP 3 is ,5-fold less potent than (1,4,5)IP 3 at each IP 3 R subtype ( Figures 7A and B , Tables 1 Figure 6 . Interactions of (1, 4, 6 and 2). This is consistent with functional assays of smooth muscle [25] and with our results from native IP 3 R (largely IP 3 R2) in rat hepatocytes, where DpEC 50 was 0.5760.03 for (1,4,5)IP 3 (pEC 50 = 6.8160.02) and MG(1,4,5)IP 3 (pEC 50 = 6.2460.01) (Taylor CW, unpublished data). These results establish that MG(1,4,5)IP 3 interacts similarly with all three IP 3 R subtypes and that it is less potent than (1,4,5)IP 3 . In aqueous solution, the triphenylmethane component of MG(1,4,5)IP 3 exists as a mixture of several inter-converting species, whose relative proportions are sensitive to pH [49] . At pH 7.4, a colourless triphenylmethanol form with a tetrahedral structure is likely to co-exist with the coloured propeller-shaped form shown in Figures 1B and 7F . Because the earlier surface plasma resonance experiments [25, 48] and our analyses were performed at similar pH, we assume that the proportions of the two forms were similar in each analysis.
In equilibrium-competition binding assays in CLM using cerebellar membranes, which predominantly express IP 3 R1 [14] , (1, 4, 5 Figure 7E) . A weak partial agonist, by contrast, would be expected, at concentrations sufficient to evoke a response, to occupy enough IP 3 R to shift the concentrationdependence of the response to (1,4,5)IP 3 to higher concentrations [4] . These results establish that MG(1,4,5)IP 3 is not a partial agonist of IP 3 R1. We conclude that MG(1,4,5)IP 3 is a full agonist of IP 3 R with an affinity that is ,7-fold less than that of (1,4,5)IP 3 .
Discussion
The primary sequence of the IBC, which is responsible for recognition of (1,4,5)IP 3 by IP 3 R, is well conserved between IP 3 R subtypes, and in isolation the IBC from each IP 3 R subtype binds IP 3 with similar affinity [16] . Although there are high-resolution structures of this region for only IP 3 R1 [3, 7, 50, 51] , homology modelling suggests that the IBC structures of the three IP 3 R subtypes are very similar ( Figure 4D ). It is, therefore, unsurprising that structure-activity relationships for the three IP 3 R subtypes, most derived from comparisons of cells expressing mixtures of IP 3 R subtypes, are similar [45, 52, 53] . Nevertheless, residues outside the IBC, notably the SD ( Figure 1A ), reduce the affinity of the IBC to differing extents for different IP 3 R subtypes [16] . Such differences and the minor differences in the primary sequence of the IBC between IP 3 R subtypes leave open the possibility that it may be possible to develop subtype-selective ligands of IP 3 R. Hitherto, the only systematic comparison of the ligand recognition properties of homogenous populations of IP 3 R subtypes examined only ligand binding to mammalian IP 3 R expressed in insect Sf9 cells [46] . We have now extended the analysis to functional assays of mammalian IP 3 R expressed in a null background, namely DT40 cells in which the genes for all endogenous IP 3 R have been disrupted [32] (Figure 2 ).
All high-affinity inositol phosphate agonists of IP 3 R have structures equivalent to the 4,5-bisphosphate and 6-hydroxyl groups of (1,4,5)IP 3 [22, 45, 46] , and with the exception of (1,3,4)IP 3 (which was effectively inactive), all ligands examined herein retain these groups ( Figure 1B) . Most of the ligands examined were either inactive ((1,3,4)IP 3 ) or their potency relative to (1,4,5)IP 3 suggested a lack of selectivity for IP 3 Tables 1 and 2 ). The potencies of each of these agonists for each IP 3 R subtype are consistent with known structure-activity relationships [45, 46] and with the structure of (1,4,5)IP 3 bound to the IBC [3] (Figure 1A) . Loss of the 2-hydroxyl minimally affects activity, loss of either the 3-hydroxyl or 1-phosphate or inverting the orientation of the 3-hydroxyl causes the potency to decrease substantially, and addition of malachite green to the 1-phosphate of (1,4,5)IP 3 causes a modest (,7-fold) decrease in potency (Tables 1 and 2 ). We Results from functional assays of Ca 2+ release from DT40-IP 3 R1 cells ( Figure 7B ) and of equilibrium competition binding to cerebellar membranes ( Figure 7C ) compare the pEC 50 conclude that the structure-activity relationships for all three mammalian IP 3 R are broadly similar.
MG(1,4,5)IP 3 was reported to bind with unexpectedly high affinity to an N-terminal fragment of IP 3 R1 [25] , but our results, in line with subsequent analyses of smooth muscle cells from the same group [25] , suggest that MG(1,4,5)IP 3 interacts similarly with all IP 3 R subtypes and that it is a full agonist with an affinity that is ,7-fold lower than that of (1,4,5)IP 3 ( Figure 7 and Tables 2  and 3 ). This is consistent with evidence suggesting that even substantial additions to the 1-phosphate of (1,4,5)IP 3 (eg, fluorescein and 3-aminopropyl) are well-tolerated [25, 48, 54] . It is also consistent with our docking studies, which suggest that even these very large additions to the 1-phosphate moiety of (1,4,5)IP 3 do not create steric clashes within the tetrameric IP 3 R ( Figure 7F ).
The necessity of the 4,5-bisphosphate and 6-hydroxyl moieties [55] , and the considerable loss of affinity associated with modifying the 3-hydroxyl group of (1,4,5)IP 3 ( Figures 3C, D and 5C, D) restrict opportunities to tag (1,4,5)IP 3 to modifications of the 1-and 2-positions. Our previous work has shown that modification of the 2-position is compatible with high-affinity binding to IP 3 R, but it reduces efficacy [4, 56] . Our demonstration that MG(1,4,5)IP 3 is a high-affinity full agonist of IP 3 R (Figure 7 ) therefore identifies an opportunity to develop fluorescent, or otherwise modified, ligands of IP 3 R that might be expected to come close to mimicking (1,4,5)IP 3 in their interactions with IP 3 R.
Only one synthetic ligand discriminated modestly between IP 3 R subtypes. (4,5)IP 2 lacks the 1-phosphate group of the endogenous ligand, (1,4,5)IP 3 ( Figure 1B ). In keeping with considerable published evidence [45, 46] , this causes a substantial decrease in potency at all IP 3 R subtypes (Figure 4 , Tables 1 and 2 ). The loss of potency is, however, significantly less pronounced (,24-fold) for IP 3 R3 than for the other IP 3 R subtypes (,80-fold) ( Table 2) . The difference is unlikely to be due to residues with the IBC itself because the IBCs of all three IP 3 R subtypes bind (1,4,5)IP 3 with indistinguishable affinity [16] and the residues that interact with the 1-phosphate group are conserved between IP 3 R ( Figure 4C ). We instead suggest that subtype-selective interactions of the IBC with other domains, perhaps the SD, subtly modify interaction of the 1-phosphate group of (1,4,5)IP 3 with two basic residues within the IBC ( Figure 4C ).
Using homogenous populations of mammalian IP 3 R and a variety of (1,4,5)IP 3 analogues, we have shown that the three IP 3 R subtypes have very similar ligand recognition properties. However, the decrease in affinity caused by loss of the 1-phosphate group is less for IP 3 R3. Finally, we have shown that MG(1,4,5)IP 3 is a full agonist of IP 3 R with only modestly reduced affinity, suggesting that attachment of fluorescent tags to the 1-phosphate of (1,4,5)IP 3 [57] is a feasible strategy for producing modified analogues of (1,4,5)IP 3 that closely mimic the native messenger.
